Holen Sie sich die Stockscreener-App
42.20
0.38%
-0.185
Schlusskurs vom Vortag:
$42.38
Offen:
$42.03
24-Stunden-Volumen:
195.27K
Relative Volume:
0.07
Marktkapitalisierung:
$8.72B
Einnahmen:
$2.10B
Nettoeinkommen (Verlust:
$402.17M
KGV:
21.80
EPS:
1.9357
Netto-Cashflow:
$403.87M
1W Leistung:
-4.48%
1M Leistung:
-0.19%
6M Leistung:
-2.57%
1J Leistung:
-10.25%
1-Tages-Spanne:
$41.91
$42.38
1-Wochen-Bereich:
$41.91
$44.46
52-Wochen-Spanne:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, NTRA, IQV, IDXX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
42.25 | 8.75B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
603.56 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.21 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
324.81 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
256.66 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
IDXX
Idexx Laboratories Inc
|
518.88 | 40.98B | 4.45B | 1.10B | 1.06B | 13.59 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
UBS Adjusts Price Target on QIAGEN to $47 From $52, Keeps Neutral Rating - marketscreener.com
Qiagen stock holds steady as analysts see limited upside - AD HOC NEWS
Qiagen N.V. $QGEN Stake Reduced by Allianz Asset Management GmbH - MarketBeat
Qiagen stock heads into the open after a 0.25 percent dip - AD HOC NEWS
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Groupe la Francaise Has $3.25 Million Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock heads into the open after a 2.0 percent drop - AD HOC NEWS
Qiagen stock edges lower as investors look beyond recent earnings - AD HOC NEWS
Qiagen N.V. (QGEN) Stock Analysis: Exploring The 5.98% Potential Upside For Investors - DirectorsTalk Interviews
New CEO took over the reins - European Biotechnology Magazine
Qiagen stock heads into the open after a muted move on Xetra - AD HOC NEWS
Public Employees Retirement System of Ohio Purchases New Shares in Qiagen N.V. $QGEN - MarketBeat
Qiagen (QGEN) Beat Q2 Estimates And Reaffirmed Outlook, Is It Still Below Fair Value? - Yahoo Finance
Qiagen N.V.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen stock trades around 43 dollars as investors watch margins and diagnostics demand - AD HOC NEWS
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Qiagen stock holds steady as margins and stake disclosure support valuation - AD HOC NEWS
BlackRock Discloses Significant Stake in Qiagen Under AFM Rules - The Globe and Mail
Qiagen stock holds near 43 dollars as stake disclosure and margins support valuation - AD HOC NEWS
Qiagen stock holds near 43 dollars after steady analyst view - AD HOC NEWS
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Qiagen stock steadies near 43 dollars as latest quarter shows modest growth - AD HOC NEWS
Q3 2025 Qiagen NV Earnings Call Transcript - GuruFocus
Qiagen stock holds mid-40 dollar level as analysts stick to hold ratings - AD HOC NEWS
Plant Virome Diagnostics Outlook 2026-2030 Featuring Profiles of Illumina, Thermo Fisher Scientific and Qiagen - Yahoo Finance
Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
List of 26 Acquisitions by Qiagen (Sep 2026) - Tracxn
Qiagen stock steadies around $43 as investors digest legal and ownership signals - AD HOC NEWS
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - Benzinga
Qiagen N.V. (QGEN) Stock Analysis: Navigating Potential Upside In Healthcare Diagnostics - DirectorsTalk Interviews
Delaware jury finds Parse infringed three genetic-sequencing patents - Reuters
Wellington Management Group LLP Trims Stock Position in Qiagen N.V. $QGEN - MarketBeat
Goldman Sachs Revealed as 2.97% Shareholder in Qiagen via AFM Filing - The Globe and Mail
Bank of America Reports 4.69% Stake in Qiagen - The Globe and Mail
Could Qiagen (QGEN) Stock Win as Its FDA Clearance Opens a New Diagnostics Market? - Yahoo Finance
10x Genomics wins jury award in Qiagen patent row (TXG:NASDAQ) - Seeking Alpha
10x Genomics Announces $4.8 Million Award in Patent Case Against Qiagen Unit - marketscreener.com
QIAGEN Launches QIAsymphony Connect for Automated Nucleic Acid Extraction - Clinical Lab Products
Qiagen launches automated nucleic acid extraction platform - Investing.com
Zacks Research Has Pessimistic Outlook of Qiagen Q3 Earnings - MarketBeat
QIAGEN Names Former Beckman Coulter President as CEO - Medical Product Outsourcing
Two potential buyers begin formal due diligence in Qiagen sales processreport (QGEN:NYSE) - Seeking Alpha
Qiagen N.V. Appoints Jonathan M. Pratt as Chief Executive Officer, Effective September 1, 2026 - marketscreener.com
QIAGEN N.V.: QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer - marketscreener.com
Qiagen names Jonathan Pratt as CEO amid takeover talks - Investing.com
Wellington Discloses 5.1% Voting Stake in Qiagen via AFM Filing - The Globe and Mail
Qiagen stock trades just below analyst target as latest earnings underpin valuation - Ad-hoc-news.de
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.07%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):